NASDAQ:ACCD Accolade - ACCD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.96 -0.31 (-2.53%) (As of 03/17/2023 08:53 PM ET) Add Compare Share Share Today's Range$11.76▼$12.4150-Day Range$7.74▼$13.3052-Week Range$4.61▼$19.39Volume685,300 shsAverage Volume726,425 shsMarket Capitalization$870.57 millionP/E RatioN/ADividend YieldN/APrice Target$13.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Accolade MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside10.8% Upside$13.25 Price TargetShort InterestHealthy4.30% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$15,838 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.49) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsBusiness Services Sector106th out of 318 stocksBusiness Services, Not Elsewhere Classified Industry38th out of 93 stocks 3.3 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.25, Accolade has a forecasted upside of 10.8% from its current price of $11.96.Amount of Analyst CoverageAccolade has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.30% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Accolade has recently decreased by 0.95%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 80.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private general practice doctor's diagnostic online appointments", "Private oncologist's appointments", "Private neurologist's appointments", and "Private otolaryngologist's appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.70. Previous Next 1.3 News and Social Media Coverage News SentimentAccolade has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Business Services companies.Search InterestOnly 2 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Accolade to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,838.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions79.01% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($6.49) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Accolade (NASDAQ:ACCD) StockAccolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.Read More Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address ACCD Stock News HeadlinesMarch 6, 2023 | finance.yahoo.comAccolade Welcomes Lyra Health to Its Trusted Partner EcosystemMarch 5, 2023 | finance.yahoo.comShould You Investigate Accolade, Inc. (NASDAQ:ACCD) At US$13.30?March 20, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 16, 2023 | finance.yahoo.comAn Intrinsic Calculation For Accolade, Inc. (NASDAQ:ACCD) Suggests It's 31% UndervaluedFebruary 16, 2023 | finance.yahoo.comMichael Hilton Joins Accolade Board of DirectorsFebruary 2, 2023 | finance.yahoo.comAnalyst Initiates Coverage On Accolade, Says 'Differentiated In Growing Market'January 31, 2023 | finance.yahoo.comWith stock up 14%, Insiders of Accolade, Inc. (NASDAQ:ACCD) must be wishing they had bought more last yearJanuary 13, 2023 | finance.yahoo.comWhy Shares of Accolade Soared This WeekMarch 20, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 12, 2023 | benzinga.comAccolade's Return On Capital Employed OverviewJanuary 12, 2023 | seekingalpha.comAccolade stock surges 20% as FQ3 revenue rises 9% Y/Y; provides fiscal 2023 outlookJanuary 12, 2023 | markets.businessinsider.comBTIG Keeps Their Hold Rating on Accolade (ACCD)January 10, 2023 | finance.yahoo.comAccolade Analyst Finds Stock Attractively Valued Post Q3 Beat, T-5 Contract WinJanuary 10, 2023 | finance.yahoo.comAnalysts Stay Bullish On Accolade Stock, Call Q3 Earnings Better Than Expected Amid Challenging BackdropJanuary 9, 2023 | finance.yahoo.comAccolade Announces Results for Fiscal Third Quarter 2023January 4, 2023 | finance.yahoo.comAccolade Announces Participation in 25th Annual Needham Growth ConferenceDecember 20, 2022 | finance.yahoo.comAccolade to Announce Fiscal Third Quarter 2023 Financial ResultsNovember 14, 2022 | finance.yahoo.comAccolade Champions Health Equity and Welcomes FOLX Health to Trusted Partner Ecosystem at HLTH 2022October 17, 2022 | seekingalpha.comAccolade: Inching Closer To Profitability (NASDAQ:ACCD) - Seeking AlphaOctober 10, 2022 | uk.finance.yahoo.comAccolade (NASDAQ:ACCD) investors are sitting on a loss of 70% if they invested a year ago - Yahoo Finance UKOctober 10, 2022 | finance.yahoo.comAccolade (NASDAQ:ACCD) investors are sitting on a loss of 70% if they invested a year agoOctober 9, 2022 | reuters.comRonaldo goalscoring accolades continue as he reaches 700 club mark - Reuters.comOctober 8, 2022 | seekingalpha.comAccolade, Inc. (ACCD) Q2 2023 Earnings Call TranscriptOctober 7, 2022 | streetinsider.comAccolade Announces Results for Fiscal Second Quarter 2023 - StreetInsider.comOctober 7, 2022 | finance.yahoo.comAccolade Posts Narrower Quarterly Loss, Tightens Annual Sales Guidance - Yahoo FinanceOctober 7, 2022 | seekingalpha.comAccolade Inc. (ACCD) Q2 2023 Results - Earnings Call Transcript - Seeking AlphaOctober 6, 2022 | investing.comAccolade Tops Q2 EPS by 6c By Investing.com - Investing.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address ACCD Company Calendar Last Earnings1/09/2023Today3/20/2023Next Earnings (Estimated)4/27/2023Fiscal Year End2/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorBusiness Services Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,350Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.25 High Stock Price Forecast$16.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+10.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($6.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,120,000.00 Net Margins-129.59% Pretax Margin-129.51% Return on Equity-28.47% Return on Assets-16.65% Debt Debt-to-Equity Ratio0.58 Current Ratio3.14 Quick Ratio3.14 Sales & Book Value Annual Sales$357.87 million Price / Sales2.43 Cash FlowN/A Price / Cash FlowN/A Book Value$12.78 per share Price / Book0.94Miscellaneous Outstanding Shares72,787,000Free Float67,474,000Market Cap$870.53 million OptionableNot Optionable Beta1.62 Key ExecutivesMr. Rajeev Singh (Age 55)Chairman & CEO Comp: $847.24kMr. Robert Cavanaugh (Age 54)Pres Comp: $644.93kMr. Stephen H. Barnes CPA (Age 51)CFO & Treasurer Comp: $602.66kMr. Michael W. Hilton (Age 58)Chief Innovation Officer Comp: $598.39kMr. Todd FriedmanSr. VP of Investor RelationsMr. Richard EskewEVP, Gen. Counsel, CCO & Sec.Ms. Carolina LoboChief Marketing OfficerMs. Kristen Keating WeeksSr. VP of Strategy, Corp. Devel. & PartnershipsMs. Jennifer HansonExec. VP of People and Culture & Chief HR OfficerMr. Todd ClardyExec. VP & GM of Mid-Market Bus.More ExecutivesKey CompetitorsInternational Money ExpressNASDAQ:IMXIConduentNASDAQ:CNDTPaysafeNYSE:PSFEAdvantage SolutionsNASDAQ:ADVRepayNASDAQ:RPAYView All CompetitorsInsiders & InstitutionsRockefeller Capital Management L.P.Bought 3,000 shares on 3/6/2023Ownership: 0.015%Parallax Volatility Advisers L.P.Bought 10,000 shares on 2/27/2023Ownership: 0.000%Rajeev SinghSold 282 sharesTotal: $3,369.90 ($11.95/share)Robert N CavanaughSold 180 sharesTotal: $2,151.00 ($11.95/share)Michael W HiltonSold 101 sharesTotal: $1,206.95 ($11.95/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock - Frequently Asked Questions Should I buy or sell Accolade stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price forecast for 2023? 16 Wall Street research analysts have issued 1 year price targets for Accolade's stock. Their ACCD share price forecasts range from $9.00 to $16.00. On average, they anticipate the company's share price to reach $13.25 in the next year. This suggests a possible upside of 10.8% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2023? Accolade's stock was trading at $7.79 at the beginning of the year. Since then, ACCD shares have increased by 53.5% and is now trading at $11.96. View the best growth stocks for 2023 here. When is Accolade's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023. View our ACCD earnings forecast. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) released its earnings results on Monday, January, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.05. The firm had revenue of $90.95 million for the quarter, compared to the consensus estimate of $87.53 million. Accolade had a negative trailing twelve-month return on equity of 28.47% and a negative net margin of 129.59%. The company's revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.31 earnings per share. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares Micro-Cap ETF (IWC).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Accolade issued on next quarter's earnings? Accolade issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $97.00 million-$101.00 million, compared to the consensus revenue estimate of $101.71 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include Honeywell International (HON), CVS Health (CVS), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? (ACCD) raised $176 million in an IPO on Thursday, July 2nd 2020. The company issued 8,800,000 shares at $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. What is Accolade's stock symbol? Accolade trades on the NASDAQ under the ticker symbol "ACCD." Who are Accolade's major shareholders? Accolade's stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (7.50%), Brown Advisory Inc. (6.93%), Geode Capital Management LLC (1.70%), Millennium Management LLC (1.51%), Bank of America Corp DE (1.09%) and Sumitomo Mitsui Trust Holdings Inc. (1.08%). Insiders that own company stock include Michael W Hilton, Rajeev Singh, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Accolade's stock price today? One share of ACCD stock can currently be purchased for approximately $11.96. How much money does Accolade make? Accolade (NASDAQ:ACCD) has a market capitalization of $870.53 million and generates $357.87 million in revenue each year. The company earns $-123,120,000.00 in net income (profit) each year or ($6.65) on an earnings per share basis. How many employees does Accolade have? The company employs 2,350 workers across the globe. How can I contact Accolade? Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com. This page (NASDAQ:ACCD) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.